![Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/98655565-88c3-426c-b446-8da9321bb7ff/gr1.jpg)
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - European Journal of Cancer
![Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 - Annals of Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 - Annals of](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8c43102a-228b-44b7-97bd-d34db195cc58/gr1.jpg)
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00 - Annals of
![Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/fd52fc9d-a5d3-469a-b1aa-ad1d4704289a/gr6_lrg.jpg)
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet
![Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients | Semantic Scholar Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fc2a5e846aba9993c4a5401d6df71a038c7d9a4a/2-Figure1-1.png)
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients | Semantic Scholar
![Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer | npj Breast Cancer Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-021-00286-w/MediaObjects/41523_2021_286_Fig1_HTML.png)
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer | npj Breast Cancer
![Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41523-021-00284-y/MediaObjects/41523_2021_284_Fig1_HTML.png)
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
![Definitive Proof that Dose-Dense Chemotherapy Is Safe and Effective for Breast Cancer | Memorial Sloan Kettering Cancer Center Definitive Proof that Dose-Dense Chemotherapy Is Safe and Effective for Breast Cancer | Memorial Sloan Kettering Cancer Center](https://www.mskcc.org/sites/default/files/styles/width_500/public/node/1067/main_image/031517_msk-00201_lores.jpg)
Definitive Proof that Dose-Dense Chemotherapy Is Safe and Effective for Breast Cancer | Memorial Sloan Kettering Cancer Center
![Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial - Annals of Oncology Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/10e03652-9f41-47d3-9d94-d8e2fbfccfbe/gr1.jpg)
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial - Annals of Oncology
![Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast ... Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c455ec0e-dd27-4a13-8e96-38019adcd529/gr1_lrg.jpg)
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast ...
![PDF) Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer PDF) Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer](https://i1.rgstatic.net/publication/237473446_Dose_Dense_Doxorubicin_and_Cyclophosphamide_Followed_by_Paclitaxel_Dose_Dense_AC_Followed_by_T_Regimen_for_Breast_Cancer/links/5617cec608aeccf998eae55f/largepreview.png)
PDF) Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel (Dose Dense AC Followed by T) Regimen for Breast Cancer
![Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer](http://article.cjcrcn.org/fileZGAZYJ/journal/article/zgazyj/2020/4/PIC/cjcr-32-04-xubinghe-2_mini.jpg)
Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
![Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study | British Journal of Cancer Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-020-0816-8/MediaObjects/41416_2020_816_Fig1_HTML.png)
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study | British Journal of Cancer
![Dr Sunil Verma on Twitter: "Dr. Gray sharing data on chemotherapy schedule impact on breast cancer outcome - overall improved outcome with dose dense approach #SABCS17 https://t.co/1TvnDXVFpu" / Twitter Dr Sunil Verma on Twitter: "Dr. Gray sharing data on chemotherapy schedule impact on breast cancer outcome - overall improved outcome with dose dense approach #SABCS17 https://t.co/1TvnDXVFpu" / Twitter](https://pbs.twimg.com/media/DQX8Re5UQAEFxnO.jpg)
Dr Sunil Verma on Twitter: "Dr. Gray sharing data on chemotherapy schedule impact on breast cancer outcome - overall improved outcome with dose dense approach #SABCS17 https://t.co/1TvnDXVFpu" / Twitter
![Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group - Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group -](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8a8551ee-4ebd-4401-b976-f51acc45c64d/gr1.jpg)
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group -
![Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12957-018-1424-4/MediaObjects/12957_2018_1424_Fig1_HTML.png)
Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text
![Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies - ScienceDirect Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804916325370-gr2.jpg)
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies - ScienceDirect
![Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4d74e81b-0230-421c-926f-dfa861831537/gr1.gif)